Somatostatin analog · acromegaly, NETs
A lab-made ring of eight amino acids that mimics somatostatin, the body's natural brake on several hormones. FDA-approved since 1988, it is used for acromegaly and for the hormone-driven diarrhea and flushing caused by certain neuroendocrine tumors. It comes as short-acting injections, a long-acting depot injection, and oral capsules.
Somatostatin is a natural hormone that restrains the release of many others. Octreotide is a smaller, stabilized analog that reproduces these actions; per its label, it is an even stronger inhibitor of growth hormone, glucagon, and insulin than somatostatin itself1. It also reduces release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, and pancreatic polypeptide, blunts the LH response to GnRH, and lowers blood flow to the gut organs1.
In acromegaly this brings growth hormone and IGF-1 down; in carcinoid tumors and VIPomas it curbs the hormone surges behind flushing and watery diarrhea. It also slows gallbladder contraction and bile release and suppresses TSH, which explains its links to gallstones and thyroid changes1.
Its approvals rest on trials in acromegaly, carcinoid syndrome, and VIPomas summarized in the labels1,2. In the randomized PROMID trial, 85 people with untreated, well-differentiated metastatic midgut neuroendocrine tumors received long-acting octreotide or placebo; median time to tumor progression was 14.3 versus 6 months, while the survival comparison was inconclusive at that analysis3. Even so, the US depot label states that effects on tumor size and growth in carcinoid syndrome and VIPomas have not been determined2. For the oral form, the phase 3 CHIASMA OPTIMAL trial randomized 56 adults with acromegaly who were controlled on injections to octreotide capsules or placebo for 36 weeks; IGF-1 stayed normal in 58% on capsules versus 19% on placebo4. Per its label, the capsule briefly increases the permeability of the gut lining between cells, which returns to baseline within hours5.
FDA-approved in 1988 as Sandostatin (Novartis), followed by Sandostatin LAR Depot (1998), oral Mycapssa capsules (2020), the Bynfezia Pen, and generic injections. Labeled uses are acromegaly, the severe diarrhea and flushing of metastatic carcinoid tumors, and the watery diarrhea of VIPomas; Mycapssa is labeled only for acromegaly maintenance in people who have responded to and tolerated octreotide or lanreotide.
Per the FDA labels, gallbladder problems are the most frequent, including sludge and gallstones that can lead to inflammation of the gallbladder or pancreas. In acromegaly, diarrhea, loose stools, nausea, abdominal discomfort, slow heart rate, high blood sugar, and underactive thyroid are also common; the capsules add headache, joint pain, sweating, and weakness. Warnings cover heart rhythm and conduction problems (complete heart block has occurred with intravenous use during surgery), high or low blood sugar, underactive thyroid, fatty stools, and lower vitamin B12 levels1,5.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.
Brand names on this page belong to their owners and are used only to identify a product. goodtides is not affiliated with those companies.